Kafetzis, D A <br/><br/>
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?  [electronic resource] 

 -  International journal of antimicrobial agents  Jan 2005 
 - 26-30 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0924-8579 
<br/><br/><label>Standard No.: </label>10.1016/j.ijantimicag.2004.09.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Amphotericin B--therapeutic use<br/>Animals<br/>Antimony<br/>Antiprotozoal Agents--therapeutic use<br/>Child<br/>Child, Preschool<br/>Female<br/>Greece<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Leishmania infantum--drug effects<br/>Leishmaniasis, Visceral--drug therapy<br/>Liposomes<br/>Male<br/>Meglumine--therapeutic use<br/>Meglumine Antimoniate<br/>Organometallic Compounds--therapeutic use<br/>Treatment Outcome